Good day and thank you for standing by. Welcome to Agora, Inc.'s First Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being ...
Viking Therapeutics' VK2735, a GLP-1 candidate, has driven significant share price gains but faces stiff competition from Eli Lilly and Novo Nordisk. Viking's Q1 earnings show no revenue, increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback